999三九品牌怎么样 申请店铺

我要投票 999三九在中草药行业中的票数:1135 更新时间:2025-04-19
999三九是哪个国家的品牌?「999三九」是 华润医药控股有限公司 旗下著名品牌。该品牌发源于广东,由创始人王春城在2007期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力999三九品牌出海!通过在本页面挂载999三九品牌的产品链接和联系邮箱,可以提高999三九产品曝光!跨境电商爆单神器,目前只要100元/年哦~

999三九怎么样

华润三九医药股份有限公司(简称“华润三九”)是大型国有控股医药上市公司,前身为深圳南方制药厂。1999年4月21日,发起设立股份制公司。2000年3月9日在深圳证券交易所挂牌上市,股票代码000999。公司于2007年11月底正式进入华润集团。2010年2月,公司名称由“三九医药股份有限公司”正式变更为"华润三九医药股份有限公司"。

华润三九主要从事医药产品的研发、生产、销售及相关健康服务。“999”品牌是中国驰名商标。公司核心产品在国内药品市场上具有相当高的占有率和知名度。三九胃泰、999感冒灵、999皮炎平、999小儿氨酚、999正天丸、999强力枇杷露、气滞胃痛颗粒、999参附注射液、999参麦注射液、舒血宁注射液、华蟾素、999新泰林(注射用五水头孢唑啉钠)、999中药配方颗粒等,单品种年销售均超过亿元人民币。其中,999感冒灵系列销量连续五年位居感冒药市场第一,2011年实现销售额13.6亿元。

2011年,华润三九实现营业收入55.25亿元,较上年同期增长26.58%,实现了公司通过外延式发展促进业务增长的目标。由于成本费用上涨,2011年实现归属于母公司所有者的净利润7.6亿元,同比上年略有降低;经营活动产生的现金流量净额9.55亿元。截至2011年底,公司总资产为76亿元。

当前,华润三九总市值为180亿元,稳定保持在医药行业上市公司前列。上市公司及所属多家生产制造单元为国家高新技术企业。华润三九先后获评“2008年度中国上市公司百强金牛奖”、“2008年度中国上市公司价值百强”、2009年中国制药工业百强”、“2010年度中国最具竞争力医药上市公司20强”等荣誉。2011年,在中国中药协会发布首批中药行业信用评价结果,华润三九获评AAA级中药企业信用荣誉,荣列排行榜榜首。

经过20多年不懈努力,尤其是并入华润集团四年来的大力变革,华润三九现已发展成为国内大型医药类上市公司。华润三九逐步形成了自身的优势和实力。品牌优势:公司具有较强的细分市场产品品牌运作经验,“999”品牌知名度高,目标客户接受度高,是感冒药和皮肤药市场的领导品牌。近期,由世界第二大传播服务集团WPP发布的《2012中国最具价值品牌TOP50强榜单》中,“999”品牌再度入选其中。此次共有“999”、云南白药、同仁堂3个医药品牌入选。

China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned listed pharmaceutical company, formerly known as Shenzhen Southern pharmaceutical factory. On April 21, 1999, the establishment of a joint stock company was initiated. On March 9, 2000, it was listed on Shenzhen stock exchange with the stock code of 000999. The company officially entered China Resources Group at the end of November 2007. In February 2010, the company name was officially changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". CR 39 is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. "999" brand is a well-known trademark in China. The company's core products have a very high share and popularity in the domestic drug market. Sanjiu Weitai, 999 Ganmaoling, 999 piyanping, 999 paediatric aminophenol, 999 Zhengtian pill, 999 Qiangli loquat dew, Qizhi Weitong granules, 999 Shenfu injection, 999 Shenmai injection, Shuxuening injection, Cinobufacin, 999 Xintailin (cefazolin sodium pentahydrate for injection), 999 traditional Chinese medicine formula granules, etc. the annual sales of each single variety are more than RMB 100 million. Among them, the sales volume of 999 Ganmaoling series ranked first in the cold medicine market for five consecutive years, and achieved a sales volume of 1.36 billion yuan in 2011. In 2011, Cr 39 achieved an operating revenue of 5.525 billion yuan, an increase of 26.58% over the same period of the previous year, and achieved the company's goal of promoting business growth through extensive development. Due to the increase of cost, the net profit attributable to the owners of the parent company was RMB 760 million in 2011, slightly lower than the previous year; the net cash flow from operating activities was RMB 955 million. By the end of 2011, the company's total assets were 7.6 billion yuan. At present, the total market value of Cr 39 is 18 billion yuan, which is stable in the forefront of Listed Companies in the pharmaceutical industry. The listed company and its production and manufacturing units are national high-tech enterprises. China Resources 39 has been awarded the "2008 golden bull award of China's top 100 listed companies", "2008 top 100 value of China's listed companies", "2009 Top 100 pharmaceutical industry of China", "2010 Top 20 most competitive pharmaceutical listed companies of China" and other honors. In 2011, the first batch of credit evaluation results of traditional Chinese medicine industry were released in China Association of traditional Chinese medicine, and Cr 39 won the credit honor of AAA level traditional Chinese medicine enterprise, ranking first in the list. After more than 20 years of unremitting efforts, especially the great changes in four years since it was incorporated into China Resources Group, China Resources 39 has developed into a large-scale pharmaceutical listed company in China. China Resources has gradually formed its own advantages and strength. Brand advantage: the company has strong experience in brand operation of products in the market segment, "999" brand has high popularity and high acceptance of target customers. It is the leading brand in cold medicine and skin medicine market. Recently, in the list of top 50 most valuable brands in China 2012 released by WPP, the world's second largest communication service group, "999" brand has been selected again. This time, "999", Yunnan Baiyao and Tongrentang were selected.

本文链接: https://brand.waitui.com/815c90ce7.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

后视摄像头图像无法显示,克莱斯勒在美召回48494辆汽车

当地时间4月19日,美国国家公路交通安全管理局(NHTSA)文件披露,由于显示模块可能无法显示后视摄像头图像,克莱斯勒将召回部分2023-2025年款阿尔法·罗密欧Tonale托纳利和道奇大黄蜂,共计48494辆。(界面)

21分钟前

一季度北京地区进出口7198.9亿元 汽车产业拉动出口增长

4月19日,据北京海关消息,今年一季度北京地区(含中央在京单位)进出口7198.9亿元。其中,出口1480.9亿元,较去年同期增长2.2%。北京外贸含“新”量进一步提升。一季度,北京地区汽车产业出口128.1亿元,同比增长56%,上拉同期地区出口增速3.2个百分点,拉动作用最强。同期,医药健康产业、绿色低碳产业分别出口31.6亿元、19亿元,同比分别增长5.8%、119.1%。

21分钟前

上海国际集团与宝山区签署战略合作框架协议 支持绿色低碳、新材料、机器人等发展

4月19日,上海国际集团与宝山区签署战略合作框架协议。双方将通过北转型基金提级扩募,重点支持宝山绿色低碳、新材料、机器人及智能制造等主导产业发展,以全链条金融服务赋能科创产业升级,并加强上市平台培育。(财联社)

21分钟前

一季度重庆外贸进出口总值1651.4亿元 同比增长4.1%

4月19日,重庆海关发布消息称,2025年一季度,重庆外贸进出口总值为1651.4亿元(人民币,下同),同比增长4.1%。据重庆海关介绍,2025年一季度,东盟是重庆第一大贸易伙伴,进出口281.4亿元,同比增长10.5%。此外,重庆对拉美、中东、非洲等新兴市场分别同比增长30.9%、9.2%、41.2%,外贸“朋友圈”持续扩大。

21分钟前

改善患者肢体运动功能 “植入式迷走神经刺激系统”临床试验启动

4月19日,国家卫生健康委组织实施“百万减残”工程重点推广项目,我国自主研发的“植入式迷走神经刺激系统”临床试验正式全国启动。该项目有望成为我国卒中后残疾防控的重要手段。迷走神经电刺激作为一种微创手术,可以辅助脑卒中患者康复治疗。数据显示,该技术能够在卒中后康复黄金期6月以后,帮助患者持续重建神经功能,明显改善患侧肢体运动功能。(财联社)

21分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询